Grace Therapeutics

GTx-104 is an injectable nimodipine formulation for treating aneurysmal subarachnoid hemorrhage, offering potential advantages over oral administration.

GTx-104 is a clinical-stage injectable nimodipine formulation for intravenous use in aSAH patients, using nanoparticle technology to enable peripheral IV infusion.

aSAH involves bleeding in the brain’s subarachnoid space, often caused by aneurysm rupture, with high mortality and dependence rates among patients.

Mr. Davis has nearly 30 years of experience as a Chief Financial Officer in publicly traded life science companies, with expertise in financial reporting, internal controls, and business processes.

Grace Therapeutics is a late-stage biopharma company with drug candidates addressing rare and orphan diseases.

Grace Therapeutics develops drug candidates for rare and orphan diseases, aiming to enhance efficacy, reduce side effects, and improve drug delivery convenience through novel technologies.

Grace Therapeutics develops drug delivery methods to disrupt standard care for various diseases.

LifeSci Advisors Mike Moyer Managing Director T: 617-308-4306 mmoyer@lifesciadvisors.com

Grace Therapeutics is poised to disrupt the long-established standard of care in aneurysmal subarachnoid hemorrhage (aSAH) — a rare, life-threatening disease caused by the rupture of an aneurysm deep inside the brain.

We are committed to making our website accessible and inclusive. Our journey with website accessibility began on 2/19/2024 and our efforts are ongoing. Our website team implements continuous improvements over time. We regularly test for accessibility and remediate our findings as needed.

Grace Therapeutics is attending healthcare industry and investor conferences in November 2026. The late-stage biopharma company is developing GTx-104, an injectable nimodipine formulation for IV infusion in aSAH patients. The events provide a platform for the company to engage with stakeholders and showcase its clinical-stage pipeline.

Nov 2026Grace Therapeutics, Inc.News article

Grace Therapeutics presents at the H.C. Wainwright 28th Annual Global Investment Conference. The company develops GTx-104, an injectable nimodipine formulation for intravenous infusion in aSAH patients. CEO Prashant Kohli will speak during the event.

Sep 2026Grace Therapeutics, Inc.News article

Grace Therapeutics reports first-quarter 2027 financial results and updates on its late-stage pipeline. The company advances **GTx-104**, an injectable nimodipine formulation for intravenous infusion, targeting patients with **aneurysmal subarachnoid hemorrhage (aSAH)**. GTx-104 remains in clinical development to address unmet medical needs in this patient population.

Aug 2026Grace Therapeutics, Inc.News article

Grace Therapeutics secures $10 million in a private placement from new and existing investors. The biopharma company develops GTx-104, an injectable nimodipine formulation for treating aSAH patients. The funding supports late-stage advancement of its clinical-stage product.

Aug 2026Grace Therapeutics, Inc.News article